IDEAYA Biosciences Inc
IDYA32.170USD
+0.400+1.26%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.82BCap. mercado
PérdidaP/E TTM
Más Datos de IDEAYA Biosciences Inc Compañía
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Información de IDEAYA Biosciences Inc
Símbolo de cotizaciónIDYA
Nombre de la empresaIDEAYA Biosciences Inc
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 23
Dirección7000 Shoreline Ct, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504436209
Sitio Webhttps://www.ideayabio.com/
Símbolo de cotizaciónIDYA
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Ejecutivos de IDEAYA Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
7.00M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Estadísticas de accionistas
Actualizado: hace 3 horas
Actualizado: hace 3 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
Otro
57.27%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.70%
Otro
57.27%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.28%
Investment Advisor/Hedge Fund
32.25%
Hedge Fund
19.91%
Research Firm
3.93%
Venture Capital
3.62%
Pension Fund
0.95%
Individual Investor
0.91%
Bank and Trust
0.45%
Corporation
0.13%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
489
96.76M
110.37%
-16.87M
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
13.15M
15%
+9.25K
+0.07%
Sep 30, 2025
Capital Research Global Investors
6.55M
7.47%
--
--
Sep 30, 2025
Janus Henderson Investors
6.43M
7.33%
+222.10K
+3.58%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.34M
7.23%
-336.88K
-5.05%
Sep 30, 2025
The Vanguard Group, Inc.
4.90M
5.59%
-19.74K
-0.40%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-1.42K
-0.03%
Sep 30, 2025
Point72 Asset Management, L.P.
3.82M
4.35%
-1.21M
-24.12%
Sep 30, 2025
Baker Bros. Advisors LP
3.28M
3.74%
+1.16M
+54.59%
Sep 30, 2025
State Street Investment Management (US)
3.24M
3.7%
-144.86K
-4.28%
Sep 30, 2025
Adage Capital Management, L.P.
2.90M
3.31%
+1.66M
+134.24%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
Ver más
Tema Oncology ETF
Proporción3.49%
ALPS Medical Breakthroughs ETF
Proporción1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción0.83%
State Street SPDR S&P Biotech ETF
Proporción0.72%
First Trust Innovation Leaders ETF
Proporción0.7%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.45%
ProShares Ultra Nasdaq Biotechnology
Proporción0.38%
Avantis US Small Cap Equity ETF
Proporción0.29%
Invesco Nasdaq Biotechnology ETF
Proporción0.27%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
